Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry

Table 4

Clinical trials quality assessment according to Jadad score.

Authors	Was the trial described as randomized?	Was the randomization procedure described and appropriate?	Was the trial described as double-blind?	Was the method of double blinding described and appropriate?	Was the number of withdrawals/dropouts in each group mentioned?	Jadad score
Bergamaschi et al. [37]	Yes	No	Yes	No	No	2
Crippa et al. [38]	Yes	No	Yes	No	No	2
Leweke et al. [35]	Yes	No	Yes	No	Yes	3
McGuire et al. [36]	Yes	Yes	Yes	No	Yes	4

The Jadad scoring system was used for the assessment of randomized controlled trials with the following 5 items. Was the study described as randomized (Yes = 1 point, No = 0 point)? was the randomization scheme described and appropriate (Yes = 1 point, No = −1 point)? Was the study described as double-blind (Yes = 1 point, No = 0 point)? Was the method of double blinding appropriate (Yes = 1 point, No = −1 point; if the answer of item 3 was No, item 4 was not calculable)? Was there a description of dropouts and withdrawal (Yes = 1 point; No = 0 point)?